Think you know Portico?
Think again.

RESULTS YOU EXPECT.
DELIVERABILITY YOU DESERVE.

Think you know portico?

RETHINK THE PORTICO SELF-EXPANDING VALVE:

  • Achieve excellent outcomes without compromising your delivery technique1,2
  • Experience controlled, relaxed deployment, thanks to continuous hemodynamic stability3,4
  • Tackle every case, even the most tortuous anatomies, with the most deliverable valve on the market5
  • Protect future treatment options by preserving access to coronaries4

CLINICAL DATA

EXCELLENT OUTCOMES
FROM A REAL WORLD STUDY

PORTICO I MULTICENTER ADJUDICATED STUDY 941 HIGH RISK PATIENTS

30 DAY OUTCOMES: LOW RATES OF MORTALITY & STROKE1

All-cause mortality

ALL-CAUSE
MORTALITY

Disabling stroke

DISABLING
STROKE

Lowest rate of  life-threatening or disabling bleeding

LIFE-THREATENING OR DISABLING BLEEDING

NEW PERMANENT PACEMAKER

NEW PERMANENT
PACEMAKER*

1 YEAR OUTCOMES: SAFETY & EFFICACY CONFIRMED2

*A new permanent pacemaker was implanted in 161 patients, representing 17.1% of all patients regardless of pacemaker status at baseline and 18.7% of patients with no prior pacemaker.

PRODUCT FEATURES

RESPONSIVE DELIVERY
AT EVERY TURN.

THE MOST DELIVERABLE VALVE, WITH OPTIMIZED TRACKABILITY AND FLEXIBILITY5

Tackle every case, even the most complex5
HORIZONTAL AORTA

CT workup of a  horizontal aorta
CT workup of a horizontal aorta

HORIZONTAL AORTA

Successfully deployed Portico in the horizontal aorta
Successfully deployed
Portico in the horizontal aorta

TEVAR GRAFT
TEVAR GRAFT

TEVAR graft in  aortic arch
TEVAR graft in
aortic arch

TEVAR GRAFT

Successfully delivered Portico through the TEVAR graft
Successfully delivered
Portico through the
TEVAR graft

CONFIDENCE FOR TODAY
AND TOMORROW.

Maintain hemodynamic stability throughout deployment

MAINTAIN HEMODYNAMIC STABILITY
THROUGHOUT DEPLOYMENT4

  • Intra-annular position provides earlier leaflet functionality4
  • Gradual, controlled deployment gives more time to assess valve placement3,4
  • No rapid pacing during deployment3,4

Retain open access for  future treatments

RETAIN OPEN ACCESS FOR
FUTURE TREATMENTS4

  • Large open cell geometry4:
    • Preserves coronary access for future interventions4
    • Minimizes obstruction to coronary blood flow4

PORTICO VALVE ANIMATION

CONTACT US

Please provide your information below to be contacted by an Abbott representative.

Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs.

REFERENCES:

  1. Maisano F. Early commercial experience from transcatheter aortic valve implantation using the Portico™ bioprosthetic valve: 30-day outcomes in the multicentre PORTICO-1 study. EuroIntervention 2018; 14-online publish-ahead-of-print August 2018.
  2. Søndergaard L, et al. One-Year Outcomes with a Self-Expanding, Repositionable Transcatheter Heart Valve in Severe Aortic Stenosis Patients: PORTICO-I. Journal of the American College of Cardiology (2018), doi: https://doi.org/10.1016/j.jacc.2018.09.014.
  3. Portico IFU.
  4. Möllmann H et al. Portico TF EU Pre-CE Mark 30d outcomes for all 4 valve sizes. J Am Coll Cardiol Intv. 2017; 10: 1538–47.
  5. Søndergaard L. How Portico helps solve challenging cases: Horizontal aorta & calcified annulus. Webinar March 4, 2016.

Information contained herein for DISTRIBUTION outside the US ONLY. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at manuals.sjm.com for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.

PRIVACY POLICY | TERMS & CONDITIONS